Literature DB >> 32005428

Lung Transplant Pathology: An Overview on Current Entities and Procedures.

Christopher Werlein1, Allison Seidel2, Gregor Warnecke3, Jens Gottlieb4, Florian Laenger2, Danny Jonigk2.   

Abstract

Alloimmune reactions are, besides various infections, the major cause for impaired lung allograft function following transplant. Acute cellular rejection is not only a major trigger of acute allograft failure but also contributes to development of chronic lung allograft dysfunction. Analogous to other solid organ transplants, acute antibody-mediated rejection has become a recognized entity in lung transplant pathology. Adequate sensitivity and specificity in the diagnosis of alloimmune reactions in the lung can only be achieved by synoptic analysis of histopathologic, clinical, and radiological findings together with serologic and microbiologic findings.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute antibody-mediated rejection; Acute cellular rejection; Alveolar fibroelastosis; Chronic lung allograft dysfunction; Lung transplant

Mesh:

Year:  2020        PMID: 32005428     DOI: 10.1016/j.path.2019.11.003

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  3 in total

Review 1.  [Fibrotic remodeling of the lung following lung and stem-cell transplantation].

Authors:  Christopher Werlein; Max Ackermann; Thia Leandra Hoffmann; Florian Laenger; Danny Jonigk
Journal:  Pathologe       Date:  2021-01-08       Impact factor: 1.011

2.  The effect of early tracheal extubation combined with physical training on pulmonary rehabilitation of patients after lung transplantation: a randomized controlled trial.

Authors:  Ting Wu; Shufang Zhou; Bo Wu; Jingyu Chen; Xuefen Zhu; Yinghua Cai
Journal:  J Thorac Dis       Date:  2022-04       Impact factor: 2.895

3.  Analysis of nosocomial infection and risk factors in lung transplant patients: a case-control study.

Authors:  Die Meng; Rui Chang; Ren Zhu
Journal:  Ann Transl Med       Date:  2022-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.